Ultragenyx Pharmaceutical Inc. (RARE) Sees Unusually-High Trading Volume
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) saw strong trading volume on Monday . 722,351 shares changed hands during trading, an increase of 23% from the previous session’s volume of 585,658 shares.The stock last traded at $77.10 and had previously closed at $77.12.
A number of equities analysts have recently weighed in on the company. Leerink Swann reissued an “outperform” rating and issued a $94.00 price target (up from $85.00) on shares of Ultragenyx Pharmaceutical in a report on Tuesday. Wedbush reissued an “outperform” rating and issued a $92.00 price target on shares of Ultragenyx Pharmaceutical in a report on Monday. Jefferies Group set a $109.00 price target on Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a report on Sunday. Credit Suisse Group AG reissued a “buy” rating and issued a $101.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday, September 14th. Finally, Cowen and Company reissued a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Tuesday, August 9th. Three equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $97.89.
The company has a 50 day moving average of $67.59 and a 200 day moving average of $63.06. The stock’s market capitalization is $2.96 billion.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($1.46) earnings per share for the quarter, missing the consensus estimate of ($1.44) by $0.02. During the same period last year, the company earned ($0.83) earnings per share. Equities research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post ($5.96) EPS for the current fiscal year.
In other news, CEO Emil D. Kakkis sold 20,000 shares of the firm’s stock in a transaction on Friday, July 15th. The stock was sold at an average price of $50.85, for a total transaction of $1,017,000.00. Following the completion of the sale, the chief executive officer now directly owns 513,597 shares of the company’s stock, valued at approximately $26,116,407.45. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Sunil Agarwal sold 649 shares of the firm’s stock in a transaction on Thursday, July 21st. The stock was sold at an average price of $52.68, for a total value of $34,189.32. The disclosure for this sale can be found here. Insiders own 10.10% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. Pacer Advisors Inc. bought a new stake in Ultragenyx Pharmaceutical during the second quarter valued at $100,000. DIAM Co. Ltd. acquired a new stake in shares of Ultragenyx Pharmaceutical during the second quarter valued at approximately $177,000. Springbok Capital Management LLC acquired a new stake in shares of Ultragenyx Pharmaceutical during the first quarter valued at approximately $189,000. BlackRock Inc. boosted its stake in shares of Ultragenyx Pharmaceutical by 58.5% in the second quarter. BlackRock Inc. now owns 3,973 shares of the biopharmaceutical company’s stock valued at $194,000 after buying an additional 1,467 shares during the period. Finally, Creative Planning boosted its stake in shares of Ultragenyx Pharmaceutical by 16,700.0% in the second quarter. Creative Planning now owns 4,200 shares of the biopharmaceutical company’s stock valued at $205,000 after buying an additional 4,175 shares during the period. 93.06% of the stock is owned by institutional investors and hedge funds.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.
Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.